Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

3,319.65INR
26 Jul 2016
Change (% chg)

Rs-162.70 (-4.67%)
Prev Close
Rs3,482.35
Open
Rs3,488.00
Day's High
Rs3,517.95
Day's Low
Rs3,290.10
Volume
1,535,245
Avg. Vol
382,905
52-wk High
Rs4,386.60
52-wk Low
Rs2,750.05

REDY.NS

Chart for REDY.NS

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.37
Market Cap(Mil.): Rs593,880.62
Shares Outstanding(Mil.): 170.54
Dividend: 20.00
Yield (%): 0.57

Financials

  REDY.NS Industry Sector
P/E (TTM): 169.31 37.20 37.97
EPS (TTM): 20.57 -- --
ROI: -- 15.00 14.27
ROE: -- 16.08 15.48

BUZZ-India's Dr. Reddy's Labs falls ahead of earnings

** Drugmaker Dr. Reddy's Laboratories Ltd falls as much as 3.75 pct in its biggest pct loss in nearly four months

25 Jul 2016

India's Dr Reddy's in $350 million deal to buy eight U.S. drugs from Teva, Allergan

MUMBAI India's second-largest drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its U.S. business.

11 Jun 2016

BUZZ-India's Dr Reddy's falls; U.S. agency charges firm for packaging lapses

** Drugmaker Dr.Reddy's Laboratories Ltd falls as much as 2.4 pct to its lowest since May 26

09 Jun 2016

MEDIA-US Agency charges India's Dr. Reddy's for packaging lapses; co disagrees - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

09 Jun 2016

BRIEF-Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier

* Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn

31 May 2016

India's Dr Reddy's falls on weak results, Deutsche Bank forecast cut

** India's second largest drugmaker on Thursday posted a near 86 pct slump in March-quarter profit

13 May 2016

BUZZ-India's Dr Reddy's rises on FDA approval for anti-nausea drug

** Dr Reddy's Laboratories rises as much as 3.5 pct, among top pct gainers on S&P BSE Healthcare index

03 Mar 2016

BUZZ-India's Dr. Reddy's rises for 2nd day as investors cheer buyback

** Dr. Reddy's Laboratories rises as much as 5.65 pct to 3,128 rupees, posts biggest intraday percentage gain in nearly 4 months

18 Feb 2016

Earnings vs. Estimates